StockNews.com Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy

StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday morning.

Other research analysts have also issued reports about the stock. Jefferies Financial Group reaffirmed a hold rating and set a $37.00 price objective (up from $30.00) on shares of Collegium Pharmaceutical in a research note on Thursday, January 4th. Truist Financial raised their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a buy rating in a report on Monday, February 26th. Needham & Company LLC reiterated a buy rating and set a $40.00 price target on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Finally, Piper Sandler reissued an overweight rating and issued a $39.00 price objective (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $39.00.

Collegium Pharmaceutical Stock Performance

COLL opened at $37.51 on Wednesday. The stock has a 50-day moving average of $37.56 and a 200 day moving average of $31.84. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. Collegium Pharmaceutical has a 12 month low of $20.83 and a 12 month high of $40.95. The firm has a market cap of $1.23 billion, a P/E ratio of 31.79 and a beta of 1.06.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. The firm had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. As a group, research analysts forecast that Collegium Pharmaceutical will post 5.63 EPS for the current year.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Principal Securities Inc. purchased a new position in Collegium Pharmaceutical in the 4th quarter worth about $40,000. China Universal Asset Management Co. Ltd. grew its stake in Collegium Pharmaceutical by 320.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock worth $116,000 after acquiring an additional 2,877 shares in the last quarter. Assetmark Inc. grew its stake in Collegium Pharmaceutical by 25.5% in the 4th quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after acquiring an additional 1,108 shares in the last quarter. Meritage Portfolio Management purchased a new position in shares of Collegium Pharmaceutical during the first quarter worth approximately $316,000. Finally, Johnson Investment Counsel Inc. bought a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at approximately $257,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.